November 2018: Start of the clinical trial with Talidox
Swissmedic has approved the clinical study phase I with Talidox. After production met all pharmaceutical standards, InnoMedica’s quality assurance released Talidox for clinical use. Last Monday, November 12, 2018, the first cancer patient was treated with Talidox at the Cantonal Hospital of St. Gallen.
The Cantonal Hospital Graubünden was officially opened as second study center and the study physicians of the Swiss Group for Clinical Cancer Research (SAKK) have begun the recruitment of study patients. With the Inselspital in Bern, the University Hospital Basel and the Ospedale Regionale di Bellinzona e Valli, three more hospitals will follow in the next weeks.
The start of the clinical trial represents an important milestone for InnoMedica, towards which the team has worked with great dedication. Talidox gives cancer patients access to chemotherapy which, thanks to the liposomal formulation of the active substance doxorubicin, aims to achieve better distribution in the body and cause fewer side effects. After extensive preclinical testing, Talidox is now being used in patients for the first time in the phase I study.
Patients are selected by the SAKK study physicians in the respective hospitals. Contact details of the relevant physicians in the clinics St. Gallen, Chur, Bern, Basel and Bellinzona are provided by SAKK.
Further information regarding the trial can be found online: https://www.clinicaltrials.gov/